Evidence map›Paper›PMID 33923380›Full record

ArticleCancers2021

Cancer: New Needs, New Models. Is It Time for a Community Oncologist? Another Brick in the Wall.

Paolo Tralongo, Vittorio Gebbia, Sebastiano Mercadante, Roberto Bordonaro, Francesco Ferraù, Sandro Barni, Alberto Firenze

Abstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Paolo TralongoMedical Oncology Unit, Hospital Umberto I, RAO, 96100 Siracusa, Italy.
Vittorio GebbiaSection of Medical Oncology, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, 90100 Palermo, Italy.
Sebastiano MercadanteAnesthesia and Intensive Care, Pain Relief and Palliative Care Unit, La Maddalena Cancer Center, 90100 Palermo, Italy.
Roberto BordonaroMedical Oncology Unit, ARNAS Garibaldi, 95100 Catania, Italy.
Francesco FerraùMedical Oncology Unit, San Vincenzo Hospital, 98039 Taormina, Italy.
Sandro BarniMedical Oncology Unit, ASST Bergamo Ovest, 24047 Treviglio, Italy.
Alberto FirenzeRisk Management Unit, AOUP P. Giaccone, University of Palermo, 90100 Palermo, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over the last few decades, thanks to early detection, effective drugs, and personalized treatments, the natural history of cancer has radically changed. Thanks to these advances, we have observed how survival of cancer patients has increased, becoming an ever more important goal in cancer care. Effective clinical governance of survivorship care is essential to ensure a successful transition between active and post-treatment life, identifying optimization of healthcare outcomes and quality of life for patients as the primary objectives. For these reasons, potential intervention models must consider these differences to rationalize the available resources, including economic aspects. In this perspective, analyzing the different models proposed in the literature to manage this type of patients, we focus on the possible role of the so-called "community oncologist". As a trained health professional, also focused on longevity, he could represent the right management solution in all those "intermediate" clinical conditions that arise between the hospital specialist, frequently overworked, and the general practitioner, often biased by the lack of specific expertise.

Indexed as

cancer survivorshipclinical governancecommunity oncology

Identifiers

PMID33923380
PMCPMC8071576

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.